<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719092</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-18078</org_study_id>
    <secondary_id>NCI-2018-01838</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <nct_id>NCT03719092</nct_id>
  </id_info>
  <brief_title>High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant</brief_title>
  <official_title>Single, High Dose Vitamin A Replacement in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and how well high dose vitamin A works in
      preventing gastrointestinal graft versus host disease (GVHD) in participants undergoing donor
      stem cell transplant. Vitamin A deficiency is associated with increased risk of
      gastrointestinal GVHD. Vitamin A regulates growth and differentiation of intestinal cells and
      may reduce risk of gastrointestinal GVHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the feasibility and safety of pre-transplant single, high dose vitamin A
      supplementation in adult allogeneic stem cell transplant recipients until day +28 after
      transplant.

      OUTLINE: This is a dose-escalation study.

      Participants receive vitamin A compound orally (PO) or enterally once prior to stem cell
      transplant.

      After completion of study treatment, participants are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin A dose that achieves level in the upper quartile of normal range for sex in at least 2/3 cases without dose limiting toxicity</measure>
    <time_frame>Up to day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of gastrointestinal graft versus host disease</measure>
    <time_frame>Up to day 180 after stem cell transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation Recipient</condition>
  <arm_group>
    <arm_group_label>Prevention (vitamin A compound)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive vitamin A compound PO or enterally once prior to stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin A Compound</intervention_name>
    <description>Given PO or enterally</description>
    <arm_group_label>Prevention (vitamin A compound)</arm_group_label>
    <other_name>A 313</other_name>
    <other_name>Anti-Infective Vitamin</other_name>
    <other_name>Antixerophthalmic Vitamin</other_name>
    <other_name>Aquasol A</other_name>
    <other_name>Arovit</other_name>
    <other_name>Avibon</other_name>
    <other_name>Avitol</other_name>
    <other_name>Axerol</other_name>
    <other_name>Axerophthol</other_name>
    <other_name>Axerophtholum</other_name>
    <other_name>Biosterol</other_name>
    <other_name>Biovit-A</other_name>
    <other_name>Del-Vi-A</other_name>
    <other_name>Ido A 50</other_name>
    <other_name>Idrurto A</other_name>
    <other_name>Lard Factor</other_name>
    <other_name>Lard-Factor</other_name>
    <other_name>Ledovit A</other_name>
    <other_name>Micelle A</other_name>
    <other_name>Mulsal A Megadosis</other_name>
    <other_name>Oleovitamin A</other_name>
    <other_name>Ophthalamin</other_name>
    <other_name>Pedi-Vit-A</other_name>
    <other_name>Retinol, all trans-</other_name>
    <other_name>Rinocusi Vitaminico</other_name>
    <other_name>Vitamin A</other_name>
    <other_name>Vitamin A Alcohol</other_name>
    <other_name>Vitamin A USP</other_name>
    <other_name>Vitamin A1</other_name>
    <other_name>Vitaminoftalmina</other_name>
    <other_name>Vitaminum A</other_name>
    <other_name>Vogan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients planned to undergo an allogeneic stem cell transplant (SCT) with an
             human leukocyte antigen (HLA)-matched (unrelated or related) or 1 allele mismatched
             (7/8) donor or haploidentical donor who received either myeloablative or
             nonmyeloablative conditioning for hematologic malignancies are eligible

        Exclusion Criteria:

          -  Vitamin A hypersensitivity or allergy

          -  Baseline pre-transplant Vitamin A levels higher than the upper quartile of normal
             range for age

          -  Abnormal liver enzymes outside of the institutional laboratory normal range within 30
             days of screening

          -  Abnormal total, indirect, or direct bilirubin outside of the institutional laboratory
             normal range within 30 days of screening

          -  Enteral feeding intolerance

          -  Medication intolerance

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannah Choe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Dalton</last_name>
    <email>Rachel.Dalton@osumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hannah Choe, MD</last_name>
      <phone>614-293-5428</phone>
      <email>Hannah.Choe@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Hannah Choe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Hannah Choe</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

